Starlix Side Effects

Generic Name: nateglinide

Please note - some side effects for Starlix may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Side Effects of Starlix - for the Consumer

Starlix

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Starlix:

Dizziness; flu-like symptoms (fever, chills, sore throat); joint pain; upper respiratory tract infection.

Seek medical attention right away if any of these SEVERE side effects occur when using Starlix:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); symptoms of liver problems (eg, dark urine, loss of appetite, pale stools, stomach pain, unusual nausea or tiredness, yellowing of the skin or eyes); symptoms of low blood sugar (eg, anxiety, chills, fast heartbeat, headache, increased hunger, severe or persistent dizziness or drowsiness, tremors, unusual sweating, vision changes, weakness).

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

Top

Starlix Side Effects - for the Professional

Starlix

In clinical trials, approximately 2,600 patients with Type 2 diabetes were treated with Starlix® (nateglinide). Of these, approximately 1,335 patients were treated for 6 months or longer and approximately 190 patients for one year or longer.

Hypoglycemia was relatively uncommon in all treatment arms of the clinical trials. Only 0.3% of Starlix patients discontinued due to hypoglycemia. Symptoms suggestive of hypoglycemia have been observed after administration of nateglinide. These symptoms included sweating, trembling, dizziness, increased appetite, palpitations, nausea, fatigue, and weakness.

Gastrointestinal symptoms, especially diarrhea and nausea, were no more common in patients using the combination of Starlix and metformin than in patients receiving metformin alone. Likewise, peripheral edema was no more common in patients using the combination of Starlix and rosiglitazone than in patients receiving rosiglitazone alone. The following table lists events that occurred more frequently in Starlix patients than placebo patients in controlled clinical trials.

Common Adverse Events (≥ 2% in Starlix® patients) in Starlix® Monotherapy Trials (% of patients)
Placebo Starlix®
N=458 N=1441
Preferred Term
Upper Respiratory Infection 8.1 10.5
Back Pain 3.7 4.0
Flu Symptoms 2.6 3.6
Dizziness 2.2 3.6
Arthropathy 2.2 3.3
Diarrhea 3.1 3.2
Accidental Trauma 1.7 2.9
Bronchitis 2.6 2.7
Coughing 2.2 2.4
Hypoglycemia 0.4 2.4

During post-marketing experience, rare cases of hypersensitivity reactions such as rash, itching and urticaria have been reported. Similarly, cases of jaundice, cholestatic hepatitis and elevated liver enzymes have been reported.

Laboratory Abnormalities

Uric Acid: There were increases in mean uric acid levels for patients treated with Starlix alone, Starlix in combination with metformin, metformin alone, and glyburide alone. The respective differences from placebo were 0.29 mg/dL, 0.45 mg/dL, 0.28 mg/dL, and 0.19 mg/dL. The clinical significance of these findings is unknown.

Top

Side Effects by Body System - for Healthcare Professionals

General

Nateglinide is generally well tolerated with the incidence of adverse effects similar to placebo. Upper respiratory tract infections, dizziness, flu symptoms, arthropathy, and accidental trauma were reported slightly more frequently than placebo in clinical trials.

Musculoskeletal

Musculoskeletal side effects have included back pain (4.0%) and arthropathy (3.3%).

Respiratory

Respiratory side effects have included upper respiratory infection (10.5%), bronchitis (2.7%), and coughing (2.4%).

Endocrine

There were increases in mean uric acid levels for patients treated with nateglinide alone, nateglinide in combination with metformin, metformin alone, and glyburide alone. The respective differences from placebo were 0.29 mg/dL, 0.28 mg/dL, 0.28 mg/dL.

Endocrine side effects have included hypoglycemia (2.4%) and increases in uric acid.

Hypersensitivity

Hypersensitivity side effects have included rare cases of rash, itching and urticaria in postmarketing experience.

Hepatic

Hepatic side effects have included post-marketing reports of jaundice, cholestatic hepatitis, and elevated liver enzymes.

Top

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Did you find this page helpful? Yes No

(web4)